JP2019500345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500345A5 JP2019500345A5 JP2018529229A JP2018529229A JP2019500345A5 JP 2019500345 A5 JP2019500345 A5 JP 2019500345A5 JP 2018529229 A JP2018529229 A JP 2018529229A JP 2018529229 A JP2018529229 A JP 2018529229A JP 2019500345 A5 JP2019500345 A5 JP 2019500345A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mrna
- protein
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 106
- 108020004999 messenger RNA Proteins 0.000 claims description 105
- 102000004169 proteins and genes Human genes 0.000 claims description 93
- 238000000034 method Methods 0.000 claims description 74
- 230000000717 retained effect Effects 0.000 claims description 72
- 230000000692 anti-sense effect Effects 0.000 claims description 54
- 102100034391 Porphobilinogen deaminase Human genes 0.000 claims description 50
- 101710189720 Porphobilinogen deaminase Proteins 0.000 claims description 50
- 101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 claims description 50
- 101710100896 Probable porphobilinogen deaminase Proteins 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 37
- 108700028369 Alleles Proteins 0.000 claims description 29
- 230000007812 deficiency Effects 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 7
- 238000010255 intramuscular injection Methods 0.000 claims description 6
- 238000010253 intravenous injection Methods 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 208000005452 Acute intermittent porphyria Diseases 0.000 claims description 5
- 206010036182 Porphyria acute Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 37
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 35
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 32
- 102100036291 Galactose-1-phosphate uridylyltransferase Human genes 0.000 description 31
- 102100035401 Ceramide synthase 2 Human genes 0.000 description 30
- 102000004889 Interleukin-6 Human genes 0.000 description 30
- 108090001005 Interleukin-6 Proteins 0.000 description 30
- 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 30
- 102100022932 Nuclear receptor coactivator 5 Human genes 0.000 description 30
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 30
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 29
- 102100030396 Protein O-glucosyltransferase 1 Human genes 0.000 description 29
- 102100039338 Aminomethyltransferase, mitochondrial Human genes 0.000 description 28
- 108010061118 Apolipoprotein A-V Proteins 0.000 description 28
- 102000011936 Apolipoprotein A-V Human genes 0.000 description 28
- 102100036284 Hepcidin Human genes 0.000 description 28
- 101001021379 Homo sapiens Galactose-1-phosphate uridylyltransferase Proteins 0.000 description 28
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 description 28
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 28
- 101001123245 Homo sapiens Protoporphyrinogen oxidase Proteins 0.000 description 28
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 28
- 101000766332 Homo sapiens Tribbles homolog 1 Proteins 0.000 description 28
- 101000910482 Homo sapiens Uroporphyrinogen decarboxylase Proteins 0.000 description 28
- 101000760747 Homo sapiens Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 28
- 101710201965 Isovaleryl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 28
- 102100029028 Protoporphyrinogen oxidase Human genes 0.000 description 28
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 28
- 102100026387 Tribbles homolog 1 Human genes 0.000 description 28
- 102100024118 Uroporphyrinogen decarboxylase Human genes 0.000 description 28
- 102100024591 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 28
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 28
- 102100024824 3 beta-hydroxysteroid dehydrogenase type 7 Human genes 0.000 description 27
- 101150087263 Cers2 gene Proteins 0.000 description 27
- 101710155270 Glycerate 2-kinase Proteins 0.000 description 27
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 27
- 102100029237 Hexokinase-4 Human genes 0.000 description 27
- 101000761592 Homo sapiens 3 beta-hydroxysteroid dehydrogenase type 7 Proteins 0.000 description 27
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 27
- 101000974352 Homo sapiens Nuclear receptor coactivator 5 Proteins 0.000 description 27
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 27
- 101001126842 Homo sapiens Protein O-glucosyltransferase 1 Proteins 0.000 description 27
- 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 27
- 108010015181 PPAR delta Proteins 0.000 description 27
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 27
- SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 description 26
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 26
- 102100034389 Low density lipoprotein receptor adapter protein 1 Human genes 0.000 description 26
- 102100034195 Thrombopoietin Human genes 0.000 description 26
- 102100036664 Adenosine deaminase Human genes 0.000 description 25
- 102100032360 Alstrom syndrome protein 1 Human genes 0.000 description 25
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 25
- 101000797795 Homo sapiens Alstrom syndrome protein 1 Proteins 0.000 description 25
- 101000887804 Homo sapiens Aminomethyltransferase, mitochondrial Proteins 0.000 description 25
- 102100031251 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Human genes 0.000 description 24
- 101000923835 Homo sapiens Low density lipoprotein receptor adapter protein 1 Proteins 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 101001129184 Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Proteins 0.000 description 21
- 102000048988 Hemochromatosis Human genes 0.000 description 19
- 108700022944 Hemochromatosis Proteins 0.000 description 19
- 101150065637 Hfe gene Proteins 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 description 16
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 16
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 16
- 108700040193 Adenylosuccinate lyases Proteins 0.000 description 14
- 102100023167 Argininosuccinate lyase Human genes 0.000 description 14
- 108700040066 Argininosuccinate lyases Proteins 0.000 description 14
- 101150025804 Asl gene Proteins 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 101000914673 Homo sapiens Fanconi anemia group A protein Proteins 0.000 description 13
- 101000918487 Homo sapiens Fumarylacetoacetase Proteins 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 108091092195 Intron Proteins 0.000 description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 208000019423 liver disease Diseases 0.000 description 8
- 206010068783 Alstroem syndrome Diseases 0.000 description 7
- 201000005932 Alstrom Syndrome Diseases 0.000 description 7
- 101000641419 Homo sapiens V-type proton ATPase 16 kDa proteolipid subunit c Proteins 0.000 description 7
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 description 7
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 description 7
- 102100034171 V-type proton ATPase 16 kDa proteolipid subunit c Human genes 0.000 description 7
- -1 LDLAP1 Proteins 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 201000000357 hemochromatosis type 2B Diseases 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- 208000008190 Agammaglobulinemia Diseases 0.000 description 4
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 4
- 206010010099 Combined immunodeficiency Diseases 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 208000012789 Deafness-enamel hypoplasia-nail defects syndrome Diseases 0.000 description 4
- 208000010583 Dowling-Degos disease 4 Diseases 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 208000027472 Galactosemias Diseases 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 206010019629 Hepatic adenoma Diseases 0.000 description 4
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 206010020606 Hyperchylomicronaemia Diseases 0.000 description 4
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 208000000420 Isovaleric acidemia Diseases 0.000 description 4
- 108091027974 Mature messenger RNA Proteins 0.000 description 4
- 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 description 4
- 241000097929 Porphyria Species 0.000 description 4
- 208000010642 Porphyrias Diseases 0.000 description 4
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 description 4
- 208000006227 SHORT syndrome Diseases 0.000 description 4
- 208000032001 Tyrosinemia type 1 Diseases 0.000 description 4
- 208000018839 Wilson disease Diseases 0.000 description 4
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 4
- 201000004525 Zellweger Syndrome Diseases 0.000 description 4
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 4
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 4
- 201000003554 argininosuccinic aciduria Diseases 0.000 description 4
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000008230 cutaneous porphyria Diseases 0.000 description 4
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 description 4
- 201000011205 glycine encephalopathy Diseases 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 108700036927 isovaleric Acidemia Proteins 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000018191 liver inflammation Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 208000003013 permanent neonatal diabetes mellitus Diseases 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 4
- 201000007851 type 1 diabetes mellitus 20 Diseases 0.000 description 4
- 201000011296 tyrosinemia Diseases 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 108050003337 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Proteins 0.000 description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- 101710191958 Amino-acid acetyltransferase Proteins 0.000 description 3
- 108010058065 Aminomethyltransferase Proteins 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- 102000009042 Argininosuccinate Lyase Human genes 0.000 description 3
- 101710146191 Ceramide synthase 2 Proteins 0.000 description 3
- 108091004554 Copper Transport Proteins Proteins 0.000 description 3
- 102000020856 Copper Transport Proteins Human genes 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 101710090046 Galactose-1-phosphate uridylyltransferase Proteins 0.000 description 3
- 108010021582 Glucokinase Proteins 0.000 description 3
- 102000030595 Glucokinase Human genes 0.000 description 3
- 108010086524 Hepatocyte Nuclear Factor 4 Proteins 0.000 description 3
- 102100031180 Hereditary hemochromatosis protein Human genes 0.000 description 3
- 101710142822 Hereditary hemochromatosis protein Proteins 0.000 description 3
- 101710200421 Low density lipoprotein receptor adapter protein 1 Proteins 0.000 description 3
- 101710115512 Nuclear receptor coactivator 5 Proteins 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108020001991 Protoporphyrinogen Oxidase Proteins 0.000 description 3
- 102000005135 Protoporphyrinogen oxidase Human genes 0.000 description 3
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 3
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 102000015437 Uroporphyrinogen decarboxylase Human genes 0.000 description 3
- 108010064762 Uroporphyrinogen decarboxylase Proteins 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 108010022687 fumarylacetoacetase Proteins 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 3
- KMOUUZVZFBCRAM-UHFFFAOYSA-N 1,2,3,6-tetrahydrophthalic anhydride Chemical compound C1C=CCC2C(=O)OC(=O)C21 KMOUUZVZFBCRAM-UHFFFAOYSA-N 0.000 description 2
- NVFRHTFJDGAFQS-UHFFFAOYSA-N 1-(3,4,5-trihydroxyphenyl)nonan-1-one Chemical compound CCCCCCCCC(=O)C1=CC(O)=C(O)C(O)=C1 NVFRHTFJDGAFQS-UHFFFAOYSA-N 0.000 description 2
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 2
- 102000009824 Hepatocyte Nuclear Factor 1-alpha Human genes 0.000 description 2
- 108010013792 Isovaleryl-CoA Dehydrogenase Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101710112761 Protein O-glucosyltransferase 1 Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- UFDHBDMSHIXOKF-UHFFFAOYSA-N tetrahydrophthalic acid Natural products OC(=O)C1=C(C(O)=O)CCCC1 UFDHBDMSHIXOKF-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100392125 Caenorhabditis elegans gck-1 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100352374 Oryza sativa subsp. japonica PLA3 gene Proteins 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- UYVZIWWBJMYRCD-ZMHDXICWSA-N isovaleryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 UYVZIWWBJMYRCD-ZMHDXICWSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267238P | 2015-12-14 | 2015-12-14 | |
| US62/267,238 | 2015-12-14 | ||
| US201662319015P | 2016-04-06 | 2016-04-06 | |
| US62/319,015 | 2016-04-06 | ||
| PCT/US2016/066564 WO2017106283A1 (en) | 2015-12-14 | 2016-12-14 | Compositions and methods for treatment of liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019500345A JP2019500345A (ja) | 2019-01-10 |
| JP2019500345A5 true JP2019500345A5 (enrdf_load_stackoverflow) | 2020-01-30 |
Family
ID=59057460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529229A Pending JP2019500345A (ja) | 2015-12-14 | 2016-12-14 | 肝臓病の処置のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3389672A4 (enrdf_load_stackoverflow) |
| JP (1) | JP2019500345A (enrdf_load_stackoverflow) |
| CA (1) | CA3005090A1 (enrdf_load_stackoverflow) |
| WO (1) | WO2017106283A1 (enrdf_load_stackoverflow) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| CA2963288A1 (en) | 2014-10-03 | 2016-04-07 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| WO2017060731A1 (en) | 2015-10-09 | 2017-04-13 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| CA3005256A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| CN110446785B (zh) | 2017-01-23 | 2024-04-26 | 瑞泽恩制药公司 | Hsd17b13变体及其应用 |
| MX2019012169A (es) | 2017-04-11 | 2019-12-11 | Regeneron Pharma | Ensayos para evaluar la actividad de moduladores de miembros de la familia de hidroxiesteroide (17-beta) deshidrogenasa (hsd17b). |
| ES2965696T3 (es) | 2017-08-25 | 2024-04-16 | Stoke Therapeutics Inc | Oligómeros antisentido para el tratamiento de afecciones y enfermedades |
| EP3461837A1 (en) * | 2017-09-28 | 2019-04-03 | Secarna Pharmaceuticals GmbH & Co. KG | Inhibitor inhibiting the expression of pprx1 |
| SG11202003254SA (en) | 2017-10-11 | 2020-05-28 | Regeneron Pharma | Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation |
| HUE070436T2 (hu) * | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
| JP2021513851A (ja) * | 2018-02-14 | 2021-06-03 | ディープ ゲノミクス インコーポレイテッドＤｅｅｐ Ｇｅｎｏｍｉｃｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ウィルソン病に対するオリゴヌクレオチド療法 |
| IL320427A (en) * | 2018-02-21 | 2025-06-01 | Bristol Myers Squibb Co | CAMK2D antisense oligonucleotides and their uses |
| CN112020556A (zh) | 2018-03-21 | 2020-12-01 | 瑞泽恩制药公司 | 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法 |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| TWI856973B (zh) | 2018-09-19 | 2024-10-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| US10913951B2 (en) * | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
| CN111849968A (zh) * | 2019-04-30 | 2020-10-30 | 中美瑞康核酸技术(南通)研究院有限公司 | 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用 |
| WO2021034985A1 (en) * | 2019-08-19 | 2021-02-25 | Stoke Therapeutics, Inc. | Compositions and methods for modulating splicing and protein expression |
| JP2022552940A (ja) * | 2019-09-20 | 2022-12-21 | ラクティゲン セラピューティクス | 血小板減少症を治療するための核酸分子及びその応用 |
| CN114728017A (zh) * | 2019-10-14 | 2022-07-08 | 阿斯利康(瑞典)有限公司 | Pnpla3表达的调节剂 |
| EP4069255A4 (en) * | 2019-12-04 | 2024-02-21 | Pai, Athma A. | IDENTIFICATION OF NON-PRODUCTIVE SPLICE JOINTS |
| IL298063A (en) | 2020-05-11 | 2023-01-01 | Stoke Therapeutics Inc | Opa1 antisense oligomers for treatment of conditions and diseases |
| WO2021231698A1 (en) * | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
| WO2022018187A1 (en) * | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting rna binding protein sites |
| WO2022109030A1 (en) * | 2020-11-17 | 2022-05-27 | Skyhawk Therapeutics, Inc. | Rna-targeting splicing modifiers for treatment of pnpla3-associated conditions and diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866042A (en) | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
| US6294520B1 (en) | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| DE69334238D1 (de) | 1992-09-25 | 2008-09-25 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
| US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| FR2727867B1 (fr) | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
| US6936589B2 (en) | 2001-09-28 | 2005-08-30 | Albert T. Naito | Parenteral delivery systems |
| US7291461B2 (en) * | 2002-06-21 | 2007-11-06 | Ptc Therapeutics, Inc. | Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay |
| EP1874958B1 (en) * | 2005-04-01 | 2019-03-27 | University of Florida Research Foundation, Incorporated | Biomarkers of liver injury |
| WO2007047913A2 (en) | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
| CN102006890A (zh) | 2007-12-04 | 2011-04-06 | 阿尔尼拉姆医药品有限公司 | 靶向脂质 |
| KR20220084437A (ko) | 2009-06-17 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법 |
| WO2012075040A2 (en) * | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| US20140128449A1 (en) * | 2011-04-07 | 2014-05-08 | The Board Of Regents Of The University Of Texas System | Oligonucleotide modulation of splicing |
| DK2734208T3 (en) | 2011-07-19 | 2017-06-19 | Wave Life Sciences Ltd | PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
| WO2015035091A1 (en) | 2013-09-04 | 2015-03-12 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
-
2016
- 2016-12-14 EP EP16876543.6A patent/EP3389672A4/en not_active Withdrawn
- 2016-12-14 CA CA3005090A patent/CA3005090A1/en active Pending
- 2016-12-14 JP JP2018529229A patent/JP2019500345A/ja active Pending
- 2016-12-14 WO PCT/US2016/066564 patent/WO2017106283A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500345A5 (enrdf_load_stackoverflow) | ||
| Scoles et al. | Oligonucleotide therapeutics in neurodegenerative diseases | |
| AU2016200344B2 (en) | Compositions and methods for modulation of smn2 splicing in a subject | |
| JP6006120B2 (ja) | 対立遺伝子多様体の選択的低減 | |
| JP2019501892A5 (enrdf_load_stackoverflow) | ||
| JP6018506B2 (ja) | 対立遺伝子多様体の選択的低減 | |
| JP7054675B2 (ja) | 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法 | |
| CN103038349B (zh) | 调节通过miR-378实现的代谢 | |
| US20200181613A1 (en) | Compositions and methods for modulation of smn2 splicing | |
| US20120149757A1 (en) | Compositions and methods for modulation of smn2 splicing | |
| KR20080031164A (ko) | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 | |
| JP2019500345A (ja) | 肝臓病の処置のための組成物および方法 | |
| JP2019500346A5 (enrdf_load_stackoverflow) | ||
| JP2018538288A5 (enrdf_load_stackoverflow) | ||
| Doxakis | Therapeutic antisense oligonucleotides for movement disorders | |
| JP2011513238A (ja) | 平滑筋の増殖および分化を調節するマイクロｒｎａならびにこれらの使用 | |
| TW202221120A (zh) | 用於治療代謝症候群之組成物及方法 | |
| CN116209761A (zh) | 靶向rna结合蛋白位点的寡核苷酸 | |
| CN102356162A (zh) | Mir-208和mir-499在治疗心脏病症中的双重靶向 | |
| JP2018538287A5 (enrdf_load_stackoverflow) | ||
| JP2018538287A (ja) | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー | |
| Gibson | Engineered microRNA therapeutics | |
| Lim et al. | Genetic approaches for the treatment of facioscapulohumeral muscular dystrophy | |
| Latronico et al. | Therapeutic applications of noncoding RNAs | |
| Ho et al. | Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS |